|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
BioSilico 2001: The Strategic Summit on In Silico Biology | ||||||||||||||||
November 14, 2001 | ||||||||||||||||
Scientific American, The Plaza Hotel, Fifth Avenue at Central Park South, New York, NY 10019 February 19-20, 2002 This exclusive two-day conference will provide a one-of-a-kind forum to hear how the key players in the pharmaceutical, biotechnology, and computer industries plan to leverage the synthesis of their technologies to create the hottest new sector in the 21st century: the Application of Information Technology to Genomics. -Presentations by "best-of-class" innovators -Insights by strategists on how developments are likely to revolutionize multiple industries -Expert opinions on how best to manage cross-industry innovation -Ample time for formal and informal discussions that can generate new directions through networking and debate |
||||||||||||||||
Organized by: | Stephen Edgington | |||||||||||||||
Invited Speakers: | Mark J. Levin, CEO, Millennium Pharmaceuticals *TBC Tim Wells, Vice President Research, Head of Discovery, Serono Jan Mous, Chief Scientific Officer, LION bioscience Mark Murcko, VP & Chief Technology Officer, Vertex Pharmaceuticals Bill Blake, VP, High Performance Technical Computing, Compaq Manuel J. Glynias, President & CEO, NetGenics Vijay Pillai, Director, Life Science Software Development Group, Oracle Songnian Zhou, Founder, CEO and Chairman, Platform Computing Srini Chari, Director, Solution Architecture and Strategy, IBM Kenneth Carter, President and CEO, Avalon Pharmaceuticals TBA, President & CEO, Myriad Proteomics R. Mark Adams, Senior Director, Bioinformatics, Variagenics William A. Haseltine, Chairman & CEO, Human Genome Sciences Lex van der Pleog, Executive Director Metabolic Diseases, Merck & Co. Gualberto Ruano, Chief Executive Officer, Genaissance Pharmaceuticals Doros Platika, President and CEO, Curis Aris Persidis, Managing Director, RheoGene Jonathan M. Rothberg, Founder, Chairman and CEO, CuraGen Klaus Lindpaintner, Director, Roche Genetics Hoffmann-La Roche Richard T. Daly, President & CEO, Visible Genetics Kari Stefansson, President, CEO, Secretary, deCODE genetics Hugh Y. Rienhoff, Founder, Chairman and CEO, DNA Sciences Lucia Quinn, Vice President, Developing Businesses, Quest Diagnostics Douglas D. Lind, Principal, Morgan Stanley Dean Witter Alan G. Walton, Chairman, Oxford Bioscience William W. Crouse, Managing Director, Healthcare Ventures Jeffrey Augen, Director, Life Sciences Strategy, IBM Paul Herrling, Head of Research, Novartis Pharma AG* Kenneth Sorensen, Managing Partner, Array Capital Tim Rink, Chairman, Solexa TBA: Five additional company presentations |
|||||||||||||||
Deadline for Abstracts: | n/a | |||||||||||||||
Registration: | Register at www.bioedge.net If you have any problems, please contact us at: US: 800-737-1333 International: 402-996-9185 Fax: 973-429-8234 Email: biosilicoinfo@bioedge.net |
|||||||||||||||
E-mail: | w.lau@noonanrusso.com | |||||||||||||||
Posted by: | Wendy Lau | |||||||||||||||
Host: | 65.204.46.194 | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |